Literature DB >> 3718805

Debrisoquine oxidation in an Australian population.

G F Peart, J Boutagy, G M Shenfield.   

Abstract

The standard laboratory method for determination of debrisoquine phenotype has been modified and shortened with no loss of sensitivity. Debrisoquine metabolic ratios (MR) at 4 and 8 h showed excellent correlation indicating that collection time can also be shortened. Same day phenotyping is therefore possible. One hundred normal, Caucasian Australian subjects were phenotyped (46 males, 54 females) and 6% were poor metabolisers (PM) of debrisoquine. Fifty of the original subjects were also acetylation phenotyped and 34% were fast and 66% slow acetylators. One PM of debrisoquine was a fast acetylator of sulphadimidine and four PM were slow acetylators. This was a non-significant association.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718805      PMCID: PMC1401023          DOI: 10.1111/j.1365-2125.1986.tb02827.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  An improved and simplified method of detecting the acetylator phenotype.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1969-12       Impact factor: 6.318

Review 2.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

3.  Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.

Authors:  M S Lennard; J H Silas; A J Smith; G T Tucker
Journal:  J Chromatogr       Date:  1977-03-11

Review 4.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report.

Authors:  E J Lee; L K Lee
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

6.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

7.  Screening methods using sulfamethazine for determining acetylator phenotype.

Authors:  P du Souich; A J McLean; K Stoeckel; D Ohlendorf; M Gibaldi
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

8.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

Authors:  R R Shah; N S Oates; J R Idle; R L Smith; J D Lockhart
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30

10.  Debrisoquine hydroxylation capacity: problems of assessment in two populations.

Authors:  T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

View more
  12 in total

1.  Polymorphism of debrisoquine oxidation in New Zealand Caucasians.

Authors:  S Wanwimolruk; J R Denton; D G Ferry; M Beasley; J R Broughton
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

3.  Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.

Authors:  Sam Mostafa; Carl M J Kirkpatrick; Keith Byron; Leslie Sheffield
Journal:  J Neural Transm (Vienna)       Date:  2018-09-06       Impact factor: 3.575

5.  Genetically determined sparteine oxidation polymorphism in a Polish population.

Authors:  K Orzechowska-Juzwenko; J Pawlik; P Niewiński; P Milejski; J Dembowski; J Turek; A Goździk; L Swiebodzki; Z Hora
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.

Authors:  Ivelina Gueorguieva; Kimberley Jackson; Steven A Wrighton; Vikram P Sinha; Jenny Y Chien
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

7.  Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.

Authors:  J Kallio; R Lindberg; R Huupponen; E Iisalo
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

8.  Debrisoquine oxidation polymorphism in a Tasmanian population.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.

Authors:  G F Peart; J Boutagy; G M Shenfield
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.

Authors:  P A Philip; C A James; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.